

03/07/01
11057 U.S. PTO

63-08-04

Bev / 1506

Attorney Docket No.: 6169.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Commissioner for Patents
Washington, DC 20231

11000 U.S. PTO
09/800541
03/07/01

Express Mail Label No. EL 636738063US
Date of Deposit March 7, 2001

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of

Applicant(s): Liselotte Bjerre Knudsen

Title: Lowering Serum Lipids

47 pages of specification

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$710.00
Total Claims: $16 - 20 = 0 \times 18 =$	\$0
Independent Claims: $3 - 3 = 0 \times 80 =$	\$0
Total Fee:	\$710.00

Priority of Danish application no. PA 2000 00375 filed on March 8, 2000 is claimed under 35 U.S.C. 119. A certified copy will be filed at a later date.


Priority of U.S. provisional application no. 60/191,593 filed on March 20, 2000 is claimed under 35 U.S.C. 119.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$710, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 7, 2001



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6169.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
Title: Lowering Serum Lipids
Applicants: Liselotte Bjerre Knudsen

Sir:
Express Mail Label No. EL 636738063US
Date of Deposit: March 7, 2001

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Sequence Listing
6. Disk Containing Sequence Listing

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Carol McFarlane

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123



23650

PATENT TRADEMARK OFFICE